查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1660072

假性腦瘤市場:現狀分析與未來預測 (2024年～2032年)

Pseudotumor Cerebri Market: Current Analysis and Forecast (2024-2032)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計預測期內（2024-2032 年），假性腦瘤市場將以 5.5% 的顯著複合年增長率成長。假性腦瘤市場的成長主要受到肥胖症成長的推動，肥胖症是導致假性腦瘤的主要原因，尤其是在育齡女性身上。認識的提高和影像和腰椎穿刺解決方案等增強的診斷解決方案是推動假性腦瘤市場發展的因素。該市場的成長得益於對新治療方法的研究不斷增加，包括手術等微創手術和成功的醫療手段。此外，政府加強對抗神經系統疾病，對特發性顱內高壓的病理生理學研究，也促進了治療介入措施的發展，並持續擴大治療這種疾病的市場潛力。

在假性腦瘤的診斷中，神經影像學領域將在 2023 年佔據最高的市場佔有率。這種主要表現歸功於高科技影像、MRI 和 CT，這些技術很少被發現，但卻是排除顱內壓升高的其他原因（包括腫瘤和中樞神經系統形態變化）所必需的。神經影像學是診斷的關鍵組成部分，該技術很常見，並且由於其比其他方法侵入性更小、更準確、更可靠而成為醫生的選擇。儘管眼底檢查領域預計將迅速擴張，但預計近期市場成長將相對保守。這種增長歸因於假性腦瘤（特別是視乳頭水腫）的早期發現的增加，以及包括 OCT 在內的眼科影像的使用。這些工具提高了診斷的準確性並有助於更早發現疾病，因為早期治療對於避免視力喪失至關重要。此外，創新且價格合理的檢眼鏡技術的進步正在推動我們在已開發市場和新興市場的產品組合。

根據治療方式，藥物治療在假性腦瘤治療中佔有最高的市場佔有率。一線藥物為乙醯唑胺、托吡酯。這些是最常用的，因為它們可以減少腦脊髓液的形成和實際顱內壓。與其他治療方法相比，它是一種非侵入性、成本更低、更容易患者和醫生接受的治療方法，尤其是在病情嚴重程度為輕度至中度時。然而，預計未來幾年靜脈竇支架領域將具有巨大的成長潛力。這是由於治療與靜脈竇狹窄（最常見的原因）相關的假性腦瘤的療效正在顯現。靜脈竇支架置入術是一種微創方法，在控制顱內壓和改善症狀方面已被證明具有有效的效果，其長期效果可直接針對病理生理原因。

基於最終用戶，醫院部門在假性腦瘤的診斷和治療中佔有最高的市場佔有率。該醫院是一家第一線醫療機構，擁有方便使用的神經影像設施、包括腰椎穿刺在內的診斷設備，以及執行分流術和靜脈竇支架術等外科手術的能力。此外，擁有神經科醫生、眼科醫生和外科醫生等各類專科醫生的醫院治療嚴重疾病，因此該領域的需求很高。然而，由於多種因素，包括神經和眼科疾病專門治療門診的機會改善，預計未來診所部門將會擴大。

為了更了解假性腦瘤的市場介紹，我們根據其在北美（美國、加拿大和歐洲其他地區）、歐洲（德國、法國、英國、西班牙、義大利和歐洲其他地區）、亞太地區（中國、日本、印度和亞太地區其他地區）和世界其他地區的全球市場表現進行分析。由於肥胖率上升、醫療成本不斷上漲、疾病意識增強以及醫療旅遊重要性日益增加等因素，預計亞太地區未來將經歷最高的成長。醫療保健的擴張以及中國、印度和日本等亞太地區國家的尚未開發的市場使亞太地區成為一個關鍵的成長市場。

市場的主要參與者包括McKesson Corporation，參天製藥株式會社，Sanofi，Polpharma，Pfizer Inc.，Sandoz AG，Viatris Inc.，Medtronic Plc.，SOPHYSA，Teva Pharmaceutical Industries Ltd.，Medtronic Plc.等。

目錄

第1章 市場概要

  • 市場定義
  • 主要目的
  • 相關利益者
  • 限制事項

第2章 分析方法或前提條件

  • 分析流程
  • 分析方法
  • 受訪者簡介

第3章 摘要整理

  • 產業摘要
  • 各市場區隔預測
    • 市場成長的強度
  • 地區展望

第4章 市場動態

  • 促進因素
  • 機會
  • 阻礙因素
  • 趨勢
  • PESTEL分析
  • 需求面分析
  • 供給面分析
    • 企業合併·收購 (M&A)
    • 投資情境
    • 產業考察:主要Start-Ups企業及其獨家策略

第5章 價格分析

  • 價格分析:各地區
  • 價格的影響因素

第6章 全球假性腦瘤的市場收益 (2022～2032年)

第7章 市場分析:診斷

  • 眼底檢驗
  • 神經影像學
  • 腰椎穿刺
  • 其他

第8章 市場分析:各治療法

  • 脊髓液分流術
  • 視神經鞘開窗戶術
  • 靜脈洞支架置入術
  • 投藥療法

第9章 市場分析:各終端用戶

  • 醫院
  • 診所
  • 其他

第10章 市場分析:各地區

  • 北美
    • 美國
    • 加拿大
    • 其他北美地區
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 全球其他地區

第11章 價值鏈分析

  • 限制分析
  • 市場參與企業一覽

第12章 競爭情形

  • 競爭儀表板
  • 企業的市場定位分析
  • 波特的五力分析

第13章 企業簡介

  • McKesson Corporation
    • 企業概要
    • 主要的財務指標
    • SWOT分析
    • 產品系列
    • 近幾年趨勢
  • Santen Pharmaceutical Co., Ltd
  • Sanofi
  • Polpharma
  • Pfizer Inc.
  • Sandoz AG
  • Viatris Inc.
  • Medtronic plc
  • SOPHYSA
  • Teva Pharmaceutical Industries Ltd.

第14章 縮寫與前提條件

第15章 附錄

簡介目錄
Product Code: UMHE213158

Pseudotumor cerebri, also known as idiopathic intracranial hypertension (IIH), is a neurological disorder in which the pressure that surrounds the brain and spinal cord (intracranial pressure) is higher than normal, but there is no inflammation, infection, tumor, or other conditions that can explain this increase. This condition is more prevalent in pregnant women and women of childbearing age with excess body weight or obesity. The exact etiology has yet to be ascertained although it is likely related to a malfunction in the regulation of CSF. The early symptoms are usually chronic headaches, and changes in vision, for example, blurring, diplopia or temporary loss of vision, pulsating tinnitus, and increased intracranial pressure papilledema. If left untreated may lead to permanent blindness. Diagnostics consists of clinical examination and assessment, brain imaging to rule in and out other pathological possibilities, and obtaining CSF pressure by lumbar puncture. Management involves a reduction of intracranial pressure, for which some patients may be recommended to lose weight, take medications, particularly acetazolamide, undertake optic nerve sheath fenestration, or spinal fluid shunt should be used if the condition becomes extreme.

The Pseudotumor Cerebri Market is expected to grow with a significant CAGR of 5.5% during the forecast period (2024-2032). The pseudotumor cerebri market is majorly driven by increased incidences of obesity, which is a major cause of pseudotumor cerebri especially among women of childbearing age. Rising awareness and enhancing diagnostic solutions like imaging solutions and lumbar puncture solutions are the factors that drive the pseudotumor cerebri market. The growth of the market is due to the increasing research of new treatment methods, which may include minimal invasions, such as surgical operations and successful medication therapeutics. Furthermore, increased efforts by the governments to combat neurological disorders, and research on the pathophysiology of idiopathic intracranial hypertension contribute to the development of therapeutic interventions, which continue to extend the market potential for the management of this disorder.

In the diagnosis of pseudotumor cerebri, the neuroimaging segment has the highest market share in the year 2023. This dominance is due to high-tech imaging, MRI, and CT, which are required to rule out other causes of raised ICP, including tumors or altered CNS morphology, although rarely identified. Neuroimaging is an important component in diagnostics and this technique is common due to its lack of invasiveness, accuracy, and reliability as compared to other methods making it doctors' choice. While the growth of the market in the near future is relatively conservative, the fundoscopy segment is likely to show rapid expansion. This growth is attributable to the rising incidence of early recognition of pseudotumor cerebri, particularly papilledema, and the use of ophthalmic imaging, including OCT. These tools improve diagnostic precision and aid in early detection of the ailment as early treatment is critical to avoid vision loss. Also, advances in innovative and affordable fundoscopy technology have enriched product offerings in both developed and emerging markets.

Based on treatment, the medication segment has the highest market share in the treatment of pseudotumor cerebri. The first-choice drugs are acetazolamide and topiramate; they are most commonly used because they help reduce CSF formation and actual intracranial pressure. It is non-invasive, cheaper, and more easily accessible to the patient and physician than other forms of treatment, especially in cases of mild to moderate severity of the illness. However, the segment covering venous sinus stenting is expected to have great potential for growth in the future. This was attributed to the rising confirmation of the therapeutic effects in the management of pseudotumor cerebri related to venous sinus stenosis, the most prevalent cause. The approach of venous sinus stenting is less invasive and provides a long-term outcome directly targeting the pathophysiologic cause with evidenced effective outcomes in controlling the intracranial pressure and symptomatic improvement.

Based on the end-user, the hospital segment accounts for the highest market share in the diagnosis as well as in the treatment of Pseudotumor Cerebri. Hospitals are the first-line healthcare facilities with easy ability to access diagnostic equipment including neuroimaging facilities and lumbar puncture and to carry out surgical processes such as shunting or venous sinus stenting. Also, severe types of diseases are treated in hospitals with various specialists such as neurologists, ophthalmologists, and even surgeons leading to huge demand for this segment. However, the clinics segment is anticipated to expand in the future due to numerous factors such as enhanced access to outpatient clinics specialized in treating neurological and ophthalmological conditions.

For a better understanding of the market adoption of Pseudotumor Cerebri is analyzed based on its worldwide presence in regions such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific region will have the highest future growth due to factors such as rising obesity rates, escalating healthcare expenditure, improving disease awareness, and the growing importance of medical tourism. Healthcare expansion and the largely untapped markets in APAC countries such as China, India, and Japan make APAC an important growth market.

Some of the major players operating in the market include McKesson Corporation, Santen Pharmaceutical Co., Ltd., Sanofi, Polpharma, Pfizer Inc., Sandoz AG, Viatris Inc., Medtronic Plc., SOPHYSA, Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Pseudotumor Cerebri Market
  • 2.2. Research Methodology of the Pseudotumor Cerebri Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends
  • 4.5. PESTEL Analysis
  • 4.6. Demand Side Analysis
  • 4.7. Supply Side Analysis
    • 4.7.1. Merger & Acquisition
    • 4.7.2. Investment Scenario
    • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

  • 5.1. Regional Pricing Analysis
  • 5.2. Price Influencing Factors

6.GLOBAL PSEUDOTUMOR CEREBRI MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY DIAGNOSIS

  • 7.1. Fundoscopy
  • 7.2. Neuroimaging
  • 7.3. Lumbar Puncture
  • 7.4. Others

8.MARKET INSIGHTS BY TREATMENT

  • 8.1. Spinal Fluid Shunt
  • 8.2. Optic Nerve Sheath Fenestration
  • 8.3. Venous Sinus Stenting
  • 8.4. Medication

9.MARKET INSIGHTS BY END-USER

  • 9.1. Hospitals
  • 9.2. Clinics
  • 9.3. Others

10.MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11.VALUE CHAIN ANALYSIS

  • 11.1. Marginal Analysis
  • 11.2. List of Market Participants

12.COMPETITIVE LANDSCAPE

  • 12.1. Competition Dashboard
  • 12.2. Competitor Market Positioning Analysis
  • 12.3. Porter Five Forces Analysis

13.COMPANY PROFILES

  • 13.1. McKesson Corporation
    • 13.1.1. Company Overview
    • 13.1.2. Key Financials
    • 13.1.3. SWOT Analysis
    • 13.1.4. Product Portfolio
    • 13.1.5. Recent Developments
  • 13.2. Santen Pharmaceutical Co., Ltd
  • 13.3. Sanofi
  • 13.4. Polpharma
  • 13.5. Pfizer Inc.
  • 13.6. Sandoz AG
  • 13.7. Viatris Inc.
  • 13.8. Medtronic plc
  • 13.9. SOPHYSA
  • 13.10. Teva Pharmaceutical Industries Ltd.

14.ACRONYMS & ASSUMPTION

15.ANNEXURE